FACT SHEET
Company. The Painmaster™ MCT (micro current
therapy) Patch is a proprietary, non-invasive pain relief
and healing stimulation product. Painmaster™ was
developed by Newmark, Inc., an innovative medical
products company focused on the discovery,
development, manufacture and marketing of disposable
medical components and medical devices. The company
was founded in 1993 as a Connecticut corporation
dedicated to producing precision components for the
ECG electrode and IV catheter markets. In 1999,
Newmark began development of a portfolio of patented
products incorporating a broadly useful technology
platform. The intellectual property and clinical
developments of Newmark are based on micro current
electrical nerve stimulation (MENS).
Micro current flows through the
body between electrodes
Technology. The Painmaster™ MCT Patch uses
MENS as its foundation, delivering a sustained flow of
low amperage electrical current. Uniquely, the
Painmaster™ design incorporates the combination of
using the body as the electrical “switch” mechanism
coupled with a user interface indicator for positive
evidence of current flow. These patented features are
employed in all variations of the Painmaster™. The
result is a diverse range of micro current devices that
deliver clear differentiation from today’s other medical
methodologies, and provide a scalable platform to
deliver straight DC current, as well as pulsed
monophasic and biphasic currents at levels from 1
microamp (µA) up to 937 microamps (µA) within a
frequency range of 0.5 hertz (Hz) up to 500 hertz (Hz).
Product Portfolio. The design platform of the
Painmaster™ MCT Patch provides the latitude to apply
the technology as a modality for pain relief, wound
healing and iontophoresis by offering differentiated
products targeted to specific markets.
The Healing Science of Micro Current Therapy (MCT)
The lower operating current and frequency devices give
Painmaster™ the ability to address a wide range of
chronic pain applications. In the wound care market,
applying the Painmaster™ higher current, lower
frequency devices to treat post operative wounds can
accelerate healing and ultimately reduce recovery and
rehabilitation time. The Painmaster™ advanced
technology models; an Impedance Adjusted device and
a User Interface Programmable device provide the basis
for iontophoretic applications. These models have the
capability to automatically adjust current levels by
instantaneously measuring the impedance of the patient
being treated and adjusting the corresponding current
output, while incorporating a microchip that is
programmable to an unlimited number of current output
levels.
Market. There are three distinct markets for the use and
application of the Painmaster™ MCT Patch technology;
pain relief, wound healing, and the transdermal delivery
of drugs via iontophoresis.
The market for pain relieving remedies is one of the
largest in the world, estimated to reach $75 billion by
2010. An estimated 89% of adults in the U.S.
experience pain every month and 50% or more do not
achieve sufficient relief. This high degree of
dissatisfaction with the current pain relief choices
creates a very large population of pain sufferers who are
ready to try something new and very willing to switch to
a different therapy.
By contrast, the Painmaster™ MCT Patch enters an
entirely new arena of value as an advanced wound care
device. Clinical studies have demonstrated the
effectiveness of MENS in post-operative wound care.
The aging population is the key driver of the advanced
wound market as the elderly account for a significant
portion of the cases related to chronic wounds. Medical
studies indicate the addition of MENS to a moist

environment with devices such as the Painmaster™ can
accelerate normal physiological function and assist the
body’s natural current in healing wounds.
tm
Painmaster Markets
(in billions)
$7.0
Pain Relief
Wound Care
$12.0 $28.0 Iontophoresis
Iontophoresis and the market for advanced drug delivery
technologies are expanding exponentially, providing
companies the opportunity to develop second-generation
drugs based on proprietary delivery systems. Strategic
alliances between device manufacturers and
pharmaceutical companies provide a pathway to
enhance value and meet the strategic needs of all parties.
Drug delivery systems employing transdermal
technology extend the duration of a drug's action,
increase delivery to target sites, reduce delivery to
unwanted sites, and maximize drug absorption.
As the micro current driver for concentrations of
medications over a period of time to a specific location
without the use of needles, and without the
gastrointestinal side effects of oral ingestion,
Painmaster™ can be an integral part of an innovative
pharmaceutical delivery system.
Clinical Data. A pilot study was conducted during
2004-05 by Timour El-Husseini and Mahmoud El-
Sebai, Professors of Orthopedics at Ain Shams
University in Cairo, Egypt. The objective was to
determine the effects of MCT therapy on post-operative
pain for patients who had undergone total knee
arthroplasty.
The Healing Science of Micro Current Therapy (MCT)
FACT SHEET
The study results indicated a 60% reduction in pain
medications on day 1 and a 90% reduction by day 10 for
the Painmaster™ patients as compared to the control
group. Wound healing also was significantly better after
10 days of micro current therapy treatments.
Another study was conducted in 2006 at the Pain Center
of the University of Utrecht in the Netherlands under
Drs. van Wijck and von Wagner. This was a double
blind, crossover, placebo controlled study of ten patients
referred by their primary care physicians after long
periods of unsuccessful treatment for chronic back pain.
100% of the patients in the study responded to
treatment, indicating reductions in both their level of
pain and the dosage and frequency of pain medication.
Intellectual Property. The Painmaster™ MCT Patch
is approved as a Class II medical device by the FDA for
prescription use only. Newmark has enjoyed significant
success in obtaining approvals internationally as well.
Patents.
• U.S. Patent No. 6,408,211
• U.S. Patent No. 6,606,519
• European Patent Organization No. 0194441.3
• Canadian Patent No. 2,410,342
• Mexican Patent No. PA/a/2002/012168
• Brazil Patent No. P10111738-6
Approvals:
• U.S. FDA Class II Medical Device - K013167
• European Union EC Directive Reg. No.
HD 60004373
• P. R. of China SFDA Approval No.
20042261127
• Korea KFDA Approval No. 45077180
• Israel Ministry Approval No. 5680008
• Canada CMDCAS Approval No. 67242
• Mexico Registration No. 04390802187
• Brazil Registration No. 59.053.488/0001-68
• Argentina - Provisional Approval
• Japan - Provisional Approval
Contact:
Francis R. Powell
Newmark, Inc.
203-272-1158
fpowell@newmarkinc.com